Results 141 to 150 of about 63,989 (248)

Bilateral abducens nerve palsy due to septic thrombophlebitis. [PDF]

, 2019
PurposeTo report a case of septic thrombophlebitis producing bilateral abducens nerve palsy.ObservationA 65 year-old woman with recent sinus surgery experienced the onset of horizontal diplopia during treatment for bacteremia. Computer tomography of head
Robbins, Shira L, Savino, Peter J, Vu, Vincent N   +2 more
core  

Rivaroxaban alleviates hepatic sinusoidal obstruction syndrome in mice by modulating the gut microbiota and inhibiting the PI3K/Akt signaling pathway

Frontiers in Microbiology
IntroductionHepatic sinusoidal obstruction syndrome (HSOS) is a vascular liver disease with a high mortality rate, and treatment methods are limited. Rivaroxaban is an oral anticoagulant.
Wencheng Liu, Yanbin Cheng, Xue Han, Junlin Xia, Qingyu Wei, Bing Chang, Quansheng Li   +6 more
doaj   +1 more source

Medication Utilization Evaluation of Dabigatran and Rivaroxaban within a Large, Multicenter Health System. [PDF]

, 2013
Objective. The objective of this medication utilization evaluation (MUE) was to determine the appropriateness of dabigatran and rivaroxaban while also reviewing outcomes for safety and effectiveness within a large, multi-center health system. Methods.
Doolin, Meagan, Issacs, Alex N., Morse, Courtney, Nisly, Sarah A., Shiltz, Erin   +4 more
core   +1 more source

Assessing the link between rivaroxaban concentration and the onset of renal impairment in elderly patients: A retrospective observational study

Asian Journal of Medical Sciences
Background: Rivaroxaban is a widely used anticoagulant, but its impact on renal function, particularly at varying plasma concentrations, remains a critical area of investigation.
Motakatla Usha Rani , Chitra Karuppiah , Penupothu Sree Nagamani   +2 more
doaj   +1 more source

Methodological Concerns Regarding a Recent Meta‐Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Non‐Valvular Atrial Fibrillation

Clinical Cardiology, Volume 49, Issue 5, May 2026.
Omar Khalid Samir, Nikita Datta
wiley   +1 more source

The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease. [PDF]

, 2020
Sickle cell disease (SCD) is an extremely heterogeneous disease that has been associated with global morbidity and early mortality. More effective and inexpensive therapies are needed.
Ballas, Samir K
core   +1 more source

Bleeding Events Associated with Rivaroxaban Therapy in Naive Patients with Nonvalvular Atrial Fibrillation: A Longitudinal Study from a Genetic Perspective with INR Follow-Up

Medicina
Background and Objectives: Rivaroxaban is a direct-acting anticoagulant used to prevent stroke in patients with atrial fibrillation. Rivaroxaban is a substrate for P-glycoprotein, which is encoded by the ABCB1 gene. Rivaroxaban is also metabolized by the
Nur Ul Ain, Niaz Ali, Abid Ullah, Shakir Ullah, Shujaat Ahmad   +4 more
doaj   +1 more source

PENGARUH PEMBERIAN RIVAROXABAN TERHADAP PENURUNAN INSIDENSI DEEP VEIN THROMBOSIS (DVT) PASCA OPERASI TOTAL KNEE REPLACEMENT (TKR) DI RSUD DR. ZAINOEL ABIDIN BANDA ACEH [PDF]

, 2017
Deep Vein Thrombosis (DVT) merupakan gumpalan darah (trombus) yang terbentuk pada vena didalam tubuh yang memungkinkan terjadinya gangguan sirkulasi dan memblokir aliran darah ke paru-paru serta dapat menyebabkan kerusakan permanen pada katup pembuluh ...
Dian Wathani
core  

Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities ...
Shea Hogan, Michael Szarek, E. Sebastian Debus, Mark Nehler, Sonia S. Anand, Manesh R. Patel, Akos Ferenc Pap, Hsiaowei Deng, Sophie Hodge, Lloyd P. Haskell, Eva Muehlhofer, Scott E. Berkowitz, Rupert M. Bauersachs, Marc P. Bonaca   +13 more
doaj   +1 more source

Thrombosis and bleeding outcomes with warfarin conversion to rivaroxaban during the COVID-19 pandemic

South African Medical Journal
Background. In 2020, during the coronavirus disease 2019 (COVID‐19) outbreak, eligible patients were converted from warfarin to rivaroxaban therapy to limit the transmission of COVID‐19 infection. Objective.
C-Y Wang, E Schapkaitz, S Louw, B Jacobson   +3 more
doaj   +1 more source